Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair Extension in Moderate to Severe Persistent Asthma
NCT00109187Phase 3Completed
- Sponsor
- Genentech
- Start
- Jun 2002
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in asthma, sponsored by Genentech. Primary endpoint: Serious and Nonserious Adverse Events at 24 weeks. Started Jun 2002; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00109187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109187.